



AlzChem Group AG

Andreas Niedermaier, CEO
Dr. Georg Weichselbaumer, CSO

March 24th, 2020



DISCLAIMER



Cautionary note regarding forward-looking statements

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the AlzChem Group.

These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected.

Beyond disclosure requirements stipulated by law, AlzChem does not undertake any obligation to update forward-looking statements.

The previous calendar year was characterized by the presentation of two short financial years with the periods Jan-June 2018 (RGJ 2018/I) and July – Dec 2018 (RGJ 2018/II). The financial year since 1 January 2019 corresponds to the calendar year again.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices.

Please note that differences can result from the use of rounded amounts and percentages.

AGENDA

Analyst Presentation Q4/2019



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

HIGHLIGHTS

Summary of business development Q4/2019 Financial Report




FACTS & DATA

- Consistent implementation of the expansion strategy of the food supplements product portfolio (LIVADUR®)
- Strong NITRALZ® sales as a result of consistent market approach and highest quality products
- High demand of our plant growth regulator Dormex®
- Weak custom manufacturing business further impact earnings
- Strong cash flow development due to implementation of announced reduction in inventories and high cash generating power
- Sales Outlook for 2019 was slightly adjusted on the 8th of November (new Outlook: 375-385 M€) because of lower demands in the automotive sector
- Both sales (as adjusted) and EBITDA outlook could be confirmed at the year-end despite of a challenging market situation


CASH FLOW

Positive free cash flow despite major CAPEX projects






COMMENTS

- Positive effect of inventory reduction on cash flow from ongoing operations
- Investing cash flow above prior year level due to main CAPEX projects Creamino® and NITRALZ®
- Lower net cash from financing activities due to higher payout of long term loans (delta +9.5 M€) and higher repayment of short-term credit lines (delta -20.6 M€)
- High positive cash generating power



Creatine has many functions in the body





Creatine recycles ATP
STORING EFFECT

Creatine counteracts cell stress
STRESS RESISTANCE


Creatine transports energy in the cell
SHORT TERM AVAILABILITY

Creatine spares energy from feed
MATRIX

The dietary supplement with creatine in premium quality – the solution



Extension of the nitrile plants successfully completed



FINANCIAL OVERVIEW Q4/2019



Result within guidance

AlzChem Group	Q4 2018	Q4 2019	yoy %	2018 1 - 12	2019 1 - 12	yoy %
SALES (in M€)	88.0	88.4	+0.4%	375.2	376.1	+0.2%
EBITDA (in M€)	8.0	8.7	+8.3%	49.4	50.1	+1.5%
EBITDA margin (in %)	9.1%	9.8%	+0.7 pp	13.2%	13.3%	+0.2 pp
Earnings per Share (in €)	0.22	0.10	-56.2%	2.22	1.77	-20.6%

COMMENTS

- 12-month sales in line with adjusted guidance despite challenging environment (steel and automotive industry)
- EBITDA-development still on upper end of Outlook
- Successful commissioning of the new Creamino® plant in 2019
- Efficient price strategy compensates cost increases (e.g. raw material costs)
- Positive USD/EUR-currency-relation supported EBITDA development

SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	-3.6%	-1.5%
Price	2.8%	1.4%
Currency	1.0%	0.6%

AGENDA

Analyst Presentation Q4/2019



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BASICS & INTERMEDIATES SEGMENT

Our integrated system



DESCRIPTION

The "Basics & Intermediates" segment comprises the production of **basic and intermediate products** that are marketed as independent products - for example in agriculture, steel production and the automotive sector - and as raw materials for the manufacture of specialty chemicals.

SELECTED PRODUCTS




NITRALZ®




BASICS & INTERMEDIATES SEGMENT

Commissioning NITRALZ® supports Q4 success (M€)


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	+0.2%	+2.3%
Price	+3.5%	+3.7%
Currency	+0.6%	+0.7%

COMMENTS

- Q4/2019 sales ~4% above previous year figures
- Strong NITRALZ® sales as result of a consistent customer acquisition
- Stable raw material prices
- metallurgic business follows market development
- Price increases stabilized profitability

SPECIALTY CHEMICALS Segment

Our growth focus



DESCRIPTION

The "Specialty Chemicals" segment produces and sells **high-quality growth products** in the area of specialty chemicals.

SELECTED PRODUCTS

 **Creapure**®

DYHARD®

 **Dormex**®

**LIVA
DUR**®

CREAMINO


Bioselect®




SPECIALTY CHEMICALS SEGMENT

Inverse seasonal effects due to Creamino® and Custom Synthesis Products (M€)


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	-3.8%	-8.1%
Price	0.0%	+2.4%
Currency	+0.6%	+1.3%

COMMENTS

- Q4/2019 sales below previous year level (~3%)
- Lower demand in the automotive sector
- Creamino® and Creapure® are established as brand names of AlzChem
- Focus on further Creamino® customer acquisition
- High demand of plant growth regulator Dormex®
- EBITDA-Margin of ~21% (PY 24%) mainly due to one time commissioning costs of Creamino®
- Changed product mix within multi-purpose facilities and downtime costs
- Marketing expenses related to Livadur® (GER) & 'Your Encour!' (USA)

OTHER & HOLDING SEGMENT

Further activities



DESCRIPTION


The "Other & Holding" segment comprises all activities that cannot be allocated to the other segments. The segment offers **infrastructure and energy** supply services at our locations for the chemicals segments and for external customers.




OTHER & HOLDING SEGMENT

Solid growth of service sales


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	+7.0%	+1.6%
Price	+1.6%	+1.5%
Currency	0.0%	0.0%

COMMENTS


- Sales ~9% above previous year quarter
- Segment follows customer site business
- Positive EBITDA effect due to slight price increase and postponed projects (grid and infrastructure)
- YTD 2018 result was negatively affected by payback of subsidy (~1.5 M€ § 19 (2) StromNEV reduction grid costs)
- Additional cost savings to support margins

BALANCE SHEET

AlzChem Group AG (M€)




ASSETS



- Higher other non-current assets due to capex projects
- Increased deferred tax assets based on the high increase in pension liabilities
- Positive impact from inventory optimization project
- Right of use assets (leasing) have been recognized for the first time in 2019 (9.7 M€)

LIABILITIES



- Dividend payment (9.2 M€)
- Lower interest rates (pension accrual) increased other non-current liabilities and decreased equity
- Payout of bank loans in Q1/2019
- Lease liabilities have been recognized for the first time in 2019 (7.7 M€)
- Redemption of all short-term loans at record date

IMPLEMENTING OPERATING TARGETS


Focus on the key growth drivers

IMPLEMENTATION OF THE CREAMINO® GROWTH

- Increase number of trials worldwide
- Reinforce technical staff – to train distributors more intensively
- Turning trials into sales
- Initiate further studies (pig and chicken)
- Increased trade fair attendance

REALIZATION OF THE NEXT CAPACITY EXPANSIONS

- Acquisition of customer contracts
- Preparation of the final CAPEX planning
- Supervisory Board approval
- Construction of the plant



ESTABLISH FIRST SALES OF LIVADUR®

- Training pharmacists
- Push various promotion activities (Radiospots, Podcasts...)
- Analysis ASIA market entry
- First test sales in USA, branded by 'Your Encour!'


SUSTAINABILITY

- Define and set the tone with CO2 neutral growth
- Zero accidents and deviations


OUTLOOK 2020

Moderate to strong increase sales and EBITDA forecast (M€)

SALES



EBITDA



COMMENTS

- Start of the expected Creamino growth in H2 after first successful test constellations
- Reinforcement of custom manufacturing
- Further growth of NITRALZ® business
- Stable development in the metallurgic and agriculture sector

FINANCIAL CALENDAR

Upcoming dates



2020	MARCH 24	Annual Report 2019
2020	MAY 12	Quarterly Statement 1 st Quarter 2020
2020	MAY 19	Annual General Meeting 2020 – Trostberg, Germany
2020	MAY 20	Equity Forum - Frankfurt, Germany
2020	AUG 11	Half-Year Financial Report 2020
2020	NOV 11	Quarterly Statement 3 rd Quarter 2020





1,623
EMPLOYEES

M€
~376
SALES

M€
~50
EBITDA


M€
~44
OPERATING
CASHFLOW



ALZCHEM
PRODUCTS
ARE SOLD
WORLDWIDE

INNOVATION SINCE

1908



*All financial indicators relating to
YTD 2019/12 figures*



THANK YOU
FOR YOUR ATTENTION!

CONTACT

Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

WWW.ALZCHEM.COM

AGENDA

Analyst Presentation Q4/2019



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BALANCE SHEET

AlzChem Group




ALZCHEM GROUP (IN T€)	31.12.2018	31.12.2019	Deviation	
Intangible assets	870	1,541	671	77.1%
Tangible assets	144,265	165,702	21,437	14.9%
Investment properties	0	0	0	
Right of use (assets)	0	9,770	9,770	
Investments accounted for using the equity	0	0	0	
Financials assets	20	20	0	0.0%
Trade receivables	0	0	0	
Other receivables	891	470	-421	-47.2%
<i>there of Deferred tax assets for pensions</i>	0	0	0	
Deferred tax assets	24,954	34,477	9,524	38.2%
SUM NON-CURRENT ASSETS	171,000	211,981	40,981	24.0%
Inventories	78,856	74,607	-4,249	-5.4%
Trade receivables	34,351	32,501	-1,849	-5.4%
Financial assets	0	0	0	-2.3%
Other receivables	14,510	14,051	-459	-3.2%
Income tax receivables	1,977	381	-1,596	-80.7%
Cash and cash equivalents	12,857	9,061	-3,796	-29.5%
Assets classified as held for sale	0	0	0	
Other assets	0	0	0	
SUM CURRENT ASSETS	142,551	130,602	-11,949	-8.4%

ALZCHEM GROUP (IN T€)	31.12.2018	31.12.2019	Deviation	
Share capital	101,763	101,763	0	0.0%
RETAINED EARNINGS (+) / LOSS (-)	60,457	69,294	8,836	14.6%
Other comprehensive income	-32,103	-48,152	-16,049	50.0%
SHARE TO THE SHAREHOLDERS	66,970	59,757	-7,213	-10.8%
Non-controlling interests	1,421	1,592	171	12.0%
SUM EQUITY	68,392	61,350	-7,042	-10.3%
Provisions for pensions	109,960	134,629	24,669	22.4%
Other provisions	18,863	22,404	3,541	18.8%
Loans	32,577	50,747	18,170	55.8%
Finance lease liabilities	0	7,710	7,710	
Trade liabilities	0	0	0	
Other liabilities	513	513	0	0.0%
Deferred tax liabilities	2,089	4,745	2,656	127.2%
SUM NON-CURRENT LIABILITIES	164,001	220,748	56,747	34.6%
Other provisions	2,554	1,732	-821	-32.2%
Loans	25,353	11,935	-13,419	-52.9%
Finance lease liabilities	0	1,706	1,706	
Finance liabilities	0	0	0	-100.0%
Trade liabilities	30,863	24,069	-6,794	-22.0%
Other liabilities	20,859	19,172	-1,687	-8.1%
Income tax liabilities	1,529	1,870	342	22.4%
SUM CURRENT LIABILITIES	81,158	60,485	-20,673	-25.5%
Sum EQUITY AND LIABILITIES	313,551	342,583	29,032	9.3%

PENSION ACCOUNTING (IFRS)

AlzChem Group (M€)



COMMENTS

- Adjustment of market interest rate from 1.90% → 0.90% increased provision
- Continued low cash payments

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Deviation (Q4)	Dez. 18	YTD	Dev. YOY
											Dez. 19	
Revenue	94,522	100,719	91,960	88,009	92,123	96,120	99,431	88,398	389 0%	375,210	376,072	863 1%
Changes in inventories of finished goods and work in prc	5,337	-547	-2,527	3,198	7,895	-321	-11,883	-553	-3,751 -117%	5,461	-4,862	-10,323 -323%
Other income	2,589	4,010	2,370	4,464	4,427	6,114	3,670	2,936	-1,527 -34%	13,432	17,147	3,715 83%
Raw materials and consumables used	-40,876	-39,304	-37,677	-37,565	-39,541	-38,320	-33,416	-31,112	6,453 -17%	-155,422	-142,391	13,031 -35%
Employee benefits expense	-29,123	-29,502	-26,917	-28,640	-30,666	-31,497	-29,313	-30,614	-1,974 7%	-114,183	-122,090	-7,907 28%
Other expense	-17,392	-19,474	-16,806	-21,470	-21,007	-17,473	-14,925	-20,395	1,075 -5%	-75,142	-73,800	1,342 -6%
EBITDA	15,057	15,902	10,403	7,995	13,231	14,623	13,564	8,659	664 8%	49,357	50,078	721 9%
Depreciation expense	-3,720	-3,777	-3,748	-3,941	-4,297	-4,302	-4,964	-5,930	-1,989 50%	-15,186	-19,492	-4,306 109%
Impairment												
EBIT	11,337	12,124	6,655	4,055	8,934	10,321	8,601	2,730	-1,325 -33%	34,170	30,585	-3,585 -88%
Investment income	9	29	30	11	8	54	26	14	3 26%	78	102	24 218%
Other interest and similar income	84	194	162	25	37	55	24	84	59 241%	465	200	-264 -1077%
Other interest and similar expense	-697	-725	-771	-622	-1,214	-1,537	-2,359	-287	335 -54%	-2,816	-5,396	-2,580 415%
Financial result	-604	-503	-580	-587	-1,169	-1,428	-2,309	-190	397 -68%	-2,273	-5,094	-2,821 481%
Result from associates												
Result from ordinary business	10,733	11,621	6,075	3,468	7,766	8,893	6,292	2,540	-928 -27%	31,897	25,491	-6,406 -185%
Taxes on income and profit	-2,846	-3,445	-1,672	-1,170	-2,212	-2,510	-1,242	-1,381	-211 18%	-9,134	-7,345	1,788 -153%
<i>thereof income tax</i>	-2,815	-2,992	-1,520	-1,278	-2,034	-2,653	-1,651	-1,592	-314 25%	-8,606	-7,930	676 -53%
<i>thereof change from deferred taxes</i>	-31	-453	-152	108	-179	143	409	211	103 95%	-528	584	1,112 1028%
Annual result	7,886	8,176	4,403	2,298	5,553	6,383	5,050	1,159	-1,139 -50%	22,763	18,145	-4,618 -201%
<i>thereof minority interests</i>	-16	73	39	43	43	43	43	171	128 300%	138	171	33 77%
<i>thereof shares held by shareholders</i>	7,902	8,104	4,364	2,255	5,510	6,340	5,008	988	-1,267 -56%	22,625	17,974	-4,651 -206%
Result per share in EUR	0.78 €	0.80 €	0.43 €	0.22 €	0.54 €	0.62 €	0.49 €	0.10 €		2.22 €	1.77 €	

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)

	Q4 2018	Q4 2019	Deviation (QoQ)		YTD Dez.2018	YTD Dez.2019	Deviation (YoY)	
Revenue	88,009	88,398	389	0.4%	375,210	376,072	863	0.2%
Changes in inventories of finished goods and work in progress	3,198	-553	-3,751	-117.3%	5,461	-4,862	-10,323	-189.0%
Other income	4,464	2,936	-1,527	-34.2%	13,432	17,147	3,715	27.7%
Raw materials and consumables used	-37,565	-31,112	6,453	-17.2%	-155,422	-142,391	13,031	-8.4%
Employee benefits expense	-28,640	-30,614	-1,974	6.9%	-114,183	-122,090	-7,907	6.9%
Other expense	-21,470	-20,395	1,075	-5.0%	-75,142	-73,800	1,342	-1.8%
EBITDA	7,995	8,659	664	8.3%	49,357	50,078	721	1.5%
Depreciation expense	-3,941	-5,930	-1,989	50.5%	-15,186	-19,492	-4,306	28.4%
Impairment	0	0	0		0	0	0	
EBIT	4,055	2,730	-1,325	-32.7%	34,170	30,585	-3,585	-10.5%
Investment income	11	14	3	26.5%	78	102	24	30.3%
Other interest and similar income	25	84	59	241.0%	465	200	-264	-56.9%
Other interest and similar expense	-622	-287	335	-53.9%	-2,816	-5,396	-2,580	91.6%
Financial result	-587	-190	397	-67.7%	-2,273	-5,094	-2,821	124.1%
Result from associates	0	0	0		0	0	0	
Result from ordinary business	3,468	2,540	-928	-26.8%	31,897	25,491	-6,406	-20.1%
Taxes on income and profit	-1,170	-1,381	-211	18.0%	-9,134	-7,345	1,788	-19.6%
<i>thereof income tax</i>	-1,278	-1,592	-314	24.6%	-8,606	-7,930	676	-7.9%
<i>thereof change from deferred taxes</i>	108	211	103	95.4%	-528	584	1,112	-210.7%
Annual result	2,298	1,159	-1,139	-49.6%	22,763	18,145	-4,618	-20.3%
<i>thereof minority interests</i>	43	171	128	300.0%	0	0	0	
<i>thereof shares held by shareholders</i>	2,255	988	-1,267	-56.2%	22,763	18,145	-4,618	-20.3%
Result per share in EUR	0.23 €	0.11 €	0	-49.6%	2.24 €	1.78 €	0	-20.3%

CASH FLOW

AlzChem Group



CASHFLOW (IN M€)

Consolidated earnings before taxes
Depreciation on fixed and intangible assets
Decrease in pension provisions
Loss (+) / Profit (-) from the sale of non-current assets
Other non-cash income (-) and expenses (+)
Financial result
Intrestes & Taxes
Increase (+) / Decrease (-) Net Working Capital
Cashflow from ongoing operations (Net cash flow)
Cash outflows for investments in fixed assets
Cash inflows from the sale of fixed assets
Cash inflow from the acquisition / Reverse acquisition
Cashflow from investing activity
Free cashflow
Deposits (+) / Repayment (-) bank loans long-term
Repayment of bank loans long-term
Deposits (+) / Repayment (-) from short-term financing lines
Dividend payments
Payment of reduction in leasing liabilities
Payment of transaction costs of capital increases
Payments to non-controlling interests
Cashflow from financing activity
Net increase / decrease in cash and cash equivalents

Q4 2018	Q4 2019
3,531	2,540
3,941	5,930
-204	-234
	-31
-418	-2,039
587	190
-2,021	-2,210
10,897	13,918
16,314	18,063
-15,283	-9,106
0	4
-15,283	-9,102
1,031	8,961
10,200	
-2,500	-3,225
3,886	-6,099
-11,194	
	-474
1	
394	-9,799
1,425	-837

1 - 12 2018	1 - 12 2019
31,920	25,491
15,186	19,492
-724	-1,005
-9	-45
5,341	6,246
2,273	5,094
-8,424	-7,282
-10,909	-4,359
34,654	43,634
-40,127	-41,382
243	55
-39,884	-41,327
-5,230	2,306
20,560	30,102
-6,508	-7,185
2,467	-18,166
-11,194	-9,159
	-1,594
-74	-171
5,250	-6,172
21	-3,866

SEGMENT OVERVIEW BY QUARTER

AlzChem Group



SALES	2017				2018				2019				Deviation PY (Q4)		YTD Q4 2019		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€						
Basics & Intermediates	35,660	37,023	37,855	30,331	34,155	36,926	35,896	32,989	35,465	37,844	41,693	34,405	1,416	4%	139,966	149,408	9,442	7%
Specialty Chemicals	48,745	47,856	44,993	44,087	53,917	56,817	49,805	48,876	50,063	51,686	50,952	47,321	-1,554	-3%	209,414	200,022	-9,392	-4%
Other and Holding	6,773	6,767	7,037	6,797	6,450	6,971	6,259	6,145	6,595	6,591	6,786	6,672	527	8%	25,825	26,643	818	3%
<i>Group Consolidation</i>						5					0				5	0	-5	-105%
AlzChem Group	91,178	91,645	89,886	81,216	94,522	100,719	91,960	88,010	92,124	96,120	99,430	88,398	388	0%	375,210	376,072	863	0%

EBITDA	2017				2018				2019				Deviation PY (Q4)		YTD Q4 2019		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€						
Basics & Intermediates	2,179	2,577	1,735	-899	1,060	188	106	-2,242	1,038	628	3,220	360	2,602	723%	-889	5,247	6,135	-690%
Specialty Chemicals	10,954	12,012	9,079	10,664	12,648	16,128	9,485	12,431	11,711	12,919	9,218	7,837	-4,595	-59%	50,692	41,684	-9,008	-18%
Other and Holding	-570	-311	-87	-1,673	759	-262	547	-852	357	838	1,435	1,877	2,729	145%	192	4,506	4,314	>1.000%
<i>Group Consolidation</i>	874	229	-681	-415	589	-152	265	-1,341	125	239	-309	-1,414	-73	5%	-639	-1,359	-720	113%
AlzChem Group	13,437	14,508	10,047	7,676	15,057	15,902	10,402	7,996	13,231	14,623	13,564	8,659	664	8%	49,357	50,078	721	1%

EXECUTIVE TEAM

AlzChem Group AG



KLAUS ENGLMAIER, COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY Production, Engineering, Environment/Safety/Health/Quality, Technology

ANDREAS NIEDERMAIER, CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY Finance & Controlling, Company Strategy, Investor Relations & Communication, IT, Risk Management, HR, Supply Chain Management, Legal/Patents & Trademarks

DR. GEORG WEICHSELBAUMER, CSO

WITH ALZCHEM SINCE 2012

AREAS OF RESPONSIBILITY Marketing, Sales, Innovation management & Process Development, R&D, Product safety and approval



ALZCHEM GROUP LOCATIONS

Production sites and sales companies



SUNDSVALL (SE)



TROSTBERG (GER)



SCHALCHEN (GER)



HART a. d. ALZ (GER)



WALDKRAIBURG (GER)



ATLANTA (USA)




SHANGHAI (CN)

Production facilities in Germany (4) and Sweden (1) and HQ in Trostberg (GER)

Fully Integrated Business Model (“Verbund” System)

Ability to adapt production to satisfy changing end market needs

○ Segment Specialty Chemicals
○ Segment Basics & Intermediates



THE “VERBUND” SYSTEM

- Fully integrated production network
- The output of a production step serves as the basic input for the next production step
- Cost benefits
- Highly specialized production chain as a unique selling point
- Full control over the quality and specification of all products

MEGATRENDS AS GROWTH DRIVERS

Growth of the population



Healthy aging



Energy efficiency





OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot[®] SQ	Silicon nitride powder for the solar industry	Photovoltaics
	Silzot[®] HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine hydrochloride salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	NITRALZ[®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		
	Operation of the Trostberg Chemical Park (companies located at the site: AlzChem, BASF, Evonik, Aramark, VIACTIV, Degussa Bank)		
	Site services		


KEY SHARE DATA

Share Details as of March 20, 2020



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE [2020-01-17]	EUR 15.10
MARKET CAPITALIZATION	EUR 153.7m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
DESIGNATED SPONSOR	Baader Bank AG Oddo Seydler Bank AG

SHAREHOLDER STRUCTURE



** Information regarding the free float in accordance with section 2.3 of the Guide to the Equity Indices of Deutsche Börse AG, as amended.*